- Home
- OCUL
as 07-26-2024 4:00pm EST
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 851.9M | IPO Year: | 2014 |
| Target Price: | $15.71 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.00 - $11.31 | Next Earning Date: | 08-05-2024 |
| Revenue: | $59,842,000 | Revenue Growth: | 15.79% |
| Revenue Growth (this year): | 15.53% | Revenue Growth (next year): | 17.48% |
Stock Insider Trading Activity of Ocular Therapeutix Inc. (OCUL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dugel Pravin | OCUL | See Remarks | May 23 '24 | Sell | $5.79 | 21,626 | $125,214.54 | 833,353 | SEC Form 4 |
| Nayak Sanjay | OCUL | Chief Strategy Officer | May 23 '24 | Sell | $5.84 | 2,274 | $13,280.16 | 178,026 | SEC Form 4 |
| SUMMER ROAD LLC | OCUL | 10% Owner | Feb 26 '24 | Buy | $7.52 | 930,851 | $6,999,999.52 | 8,591,401 | SEC Form 4 |
| Ozden Rabia Gurses | OCUL | Chief Medical Officer | Feb 3 '24 | Sell | $4.86 | 6,346 | $30,841.56 | 153,054 | SEC Form 4 |
| Strassburger Philip C. | OCUL | General Counsel | Feb 3 '24 | Sell | $4.86 | 6,029 | $29,300.94 | 161,493 | SEC Form 4 |
| Notman Donald | OCUL | Chief Financial Officer | Feb 3 '24 | Sell | $4.86 | 6,212 | $30,190.32 | 195,356 | SEC Form 4 |
| Mattessich Antony C. | OCUL | President and CEO | Feb 3 '24 | Sell | $4.86 | 19,642 | $95,460.12 | 588,701 | SEC Form 4 |
| White Christopher G | OCUL | Chief Business Officer | Feb 3 '24 | Sell | $4.86 | 5,910 | $28,722.60 | 123,689 | SEC Form 4 |
| Mattessich Antony C. | OCUL | President and CEO | Jan 31 '24 | Sell | $4.95 | 18,338 | $90,773.10 | 427,943 | SEC Form 4 |
| White Christopher G | OCUL | Chief Business Officer | Jan 31 '24 | Sell | $4.95 | 5,147 | $25,477.65 | 89,619 | SEC Form 4 |
| Notman Donald | OCUL | Chief Financial Officer | Jan 31 '24 | Sell | $4.95 | 6,433 | $31,843.35 | 139,932 | SEC Form 4 |
| Ozden Rabia Gurses | OCUL | Chief Medical Officer | Jan 31 '24 | Sell | $4.95 | 7,764 | $38,431.80 | 92,767 | SEC Form 4 |
| Strassburger Philip C. | OCUL | General Counsel | Jan 31 '24 | Sell | $4.95 | 6,831 | $33,813.45 | 109,218 | SEC Form 4 |
| SUMMER ROAD LLC | OCUL | 10% Owner | Dec 14 '23 | Buy | $3.25 | 1,538,461 | $4,999,998.25 | 7,660,550 | SEC Form 4 |
Latest Ocular Therapeutix Inc. News
OCUL Breaking Stock News: Dive into OCUL Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
15 days ago
The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing
GlobeNewswire
17 days ago
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
GlobeNewswire
18 days ago
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Ocular Therapeutix Shares Rise After TD Cowen Upgrades Rating, Increases Price Target
MT Newswires
a month ago
TD Cowen Upgrades Ocular Therapeutix to Buy From Hold, Adjusts Price Target to $11 From $7
MT Newswires
a month ago
Sector Update: Health Care Stocks Decrease Late Afternoon
MT Newswires
a month ago
Ocular Therapeutix Shares Rise Following Clinical Development Progress Report
Compare OCUL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCUL Ocular Therapeutix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.